The first results from the VitaK-CAC Trial, “Menaquinone-7 Slows Down Progression of Coronary Artery Calcification: A Randomized, Placebo-Controlled Trial,” were presented at the 34th European Meeting on Hypertension and Cardiovascular Protection, organized by the European Society of Hypertension (ESH), held in Milan in May 23–26, 2025.
What is VitaK-CAC?
The study, “Menaquinone-7 supplementation to reduce vascular calcification in patients with coronary artery disease (VitaK-CAC trial),” was designed to explore the protective effect of vitamin K2 as MK-7 (menaquinone-7 as MenaQ7®) supplementation on slowing down the progression of coronary artery calcification (CAC), lending further understanding to the mechanism by which K2 inhibits calcification to cardiovascular vessels.
Primary Outcomes Presented
The first findings of this randomized, double-blind, placebo-controlled clinical trial were presented at the conference in Milan, showing that a two-year period of supplementation with MK-7 can slow down the progression of CAC in patients with mild to moderate coronary artery disease, irrespective of blood pressure status.
More to Come
The VitaK-CAC Trial was initiated on the heels of the groundbreaking 3-year MenaQ7® cardiovascular study’s publication. The full results are expected to be published this year and presented at additional prestigious conferences and congresses.